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Abstract
Background: Gemcitabine is an analogue of deoxycytidine with activity against several solid
tumors. In order to elucidate the mechanisms by which tumor cells become resistant to
gemcitabine, we developed the resistant subline RL-G from the human follicular lymphoma cell line
RL-7 by prolonged exposure of parental cells to increasing concentrations of gemcitabine.
Results: In vitro, the IC50 increased from 0.015 µM in parental RL-7 cells to 25 µM in the resistant
variant, RL-G. Xenografts of both cell lines developed in nude mice were treated with repeated
injections of gemcitabine. Under conditions of gemcitabine treatment which totally inhibited the
development of RL-7 tumors, RL-G derived tumors grew similarly to those of untreated animals,
demonstrating the in vivo resistance of RL-G cells to gemcitabine. HPLC experiments showed that
RL-G cells accumulated and incorporated less gemcitabine metabolites into DNA and RNA than
RL-7 cells. Gemcitabine induced an S-phase arrest in RL-7 cells but not in RL-G cells. Exposure to
gemcitabine induced a higher degree of apoptosis in RL-7 than in RL-G cells, with poly-(ADP-
ribose) polymerase cleavage in RL-7 cells. No modifications of Bcl-2 nor of Bax expression were
observed in RL-7 or RL-G cells exposed to gemcitabine. These alterations were associated with
the absence of the deoxycytidine kinase mRNA expression observed by quantitative RT-PCR in RL-
G cells. PCR amplification of désoxycytidine kinase gene exons showed a partial deletion of the
dCK gene in RL-G cells.
Conclusions: These results suggest that partial deletion of the dCK gene observed after selection
in the presence of gemcitabine is involved with resistance to this agent both in vitro and in vivo.
Background
Gemcitabine is an analogue of deoxycytidine with activity
against several solid tumors (reviewed in [1]). Gemcitab-
ine enters the cell via a facilitated nucleoside transport
mechanism [2,3] and is phosphorylated into gemcitabine
5'-monophosphate (dFd-CMP) by deoxycytidine kinase
(dCK) [4]. It is then subsequently phosphorylated by
other pyrimidine kinases to the active 5'-diphosphate
(dFd-CDP) and triphosphate (dFd-CTP) derivatives [5].
Inactivation of gemcitabine and dFd-CMP occurs by
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deamination by cytidine deaminase (CDD) and dCMP
deaminase, respectively [6,7]. Dephosphorylation of dFd-
CMP by cytoplasmic 5'-nucleotidase activities can also
prevent the production of the active forms [8].
Cytotoxic actions of gemcitabine are exerted by the phos-
phorylated metabolites [9]. The active diphosphate
metabolite, dFd-CDP, inhibits DNA synthesis indirectly
through inhibition of ribonucleotide reductase (RNR)
[10]. This effect blocks the de novo DNA synthesis pathway
and self-potentiates gemcitabine activity by decreasing
intracellular concentrations of normal deoxynucleoside
triphosphates, thereby favoring further gemcitabine phos-
phorylation and dFd-CTP incorporation into DNA
[11,12]. The other active metabolite, dFd-CTP, is incorpo-
rated into the growing DNA strand by replication synthe-
sis after which DNA polymerase is able to add one more
nucleotide before DNA polymerisation is terminated [13].
Inhibition of DNA synthesis leads to growth inhibition or
cell death. Gemcitabine can also be incorporated into
RNA and inhibit RNA synthesis. While incorporation of
gemcitabine metabolites into RNA are concentration-
dependent, the extent of RNA synthesis inhibition seems
to be cell-specific [9]. Finally gemcitabine inhibits dCMP
deaminase and CTP synthetase activities [11,14].
Various general mechanisms of resistance to gemcitabine
have been described (reviewed in [15,16]). A primary
mechanism of resistance may arise from an insufficient
intracellular concentration of dFdCTP because of an
altered activation/degradation pathway. This may results
from inefficient cellular uptake, reduced levels of gemcit-
abine activation or increased drug degradation. Defi-
ciency of dCK is the most frequent described mechanism
of resistance to gemcitabine (for review see [17]). Several
authors have described a relation between dCK activity
and sensitivity to gemcitabine in cells with an acquired
resistance to gemcitabine in cell and animal models [18-
20]. Deficiency of nucleoside transporters in tumour
plasma membranes, as well as increased activity of CDD,
dCMP deaminase or 5'-nucleotidase enzyme activities
have also been suggested as mechanisms of cellular resist-
ance to gemcitabine [2,6-8].
A second type of resistance mechanism may concern
altered interactions with intracellular targets [21]. Various
authors showed a correlation between gemcitabine resist-
ance and a increase in ribonucleotide reductase (RNR)
activity [19,21]. Finally, alterations of apoptosis-regulat-
ing genes (principally p53) also appear to be involved in
the sensitivity of tumor cells to the cytotoxic effect of gem-
citabine [22].
In order to elucidate the mechanisms by which tumor
cells become resistant to gemcitabine, we developed the
resistant subline RL-G from the human follicular lym-
phoma cell line RL-7 by prolonged exposure of parental
cells to increasing concentrations of gemcitabine. Here,
we describe the biochemical and molecular characteriza-
tion of RL-G cells in comparison to the parental RL-7 cells,
with particular reference to their differential responses to
exposure to gemcitabine. Analysis of the mechanisms of
resistance identified deficiency of dCK as the main cause
of resistance in RL-G cells in vitro and in mouse xenografts.
Results
In vitro and in vivo chemosensitivity studies
We have previously shown that RL-G cells were 2,092-fold
more resistant than RL-7 cells to gemcitabine (RL-G IC50:
25.1 ± 5.0 µM; RL-7 IC50: 0.015 ± 0.0006 µM) [23]. RL-G
cells were also cross resistant to ara-C.
We determined the effect of gemcitabine on the growth of
the RL-7 and RL-G tumors when grown subcutaneously as
xenografts in athymic nude mice. Median tumor weights
in mg of RL-7 and RL-G xenografts in Swiss nude female
mice treated or not with gemcitabine are shown in Figure
1. At day 60 after tumor injection, the RL-7 xenografts
treated with gemcitabine were significantly smaller than
the control tumors (Student t test, p = 0.04) (Fig. 1). The
T/C value for RL-7 xenografts was 0.24. Conversely, no
significant differences in tumor size were observed
between the treated and control groups of mice xenotrans-
planted with the RL-G cells. The T/C value for RL-G
xenografted mice was 0.98. These results indicate that RL-
7 tumors were significantly more sensitive to gemcitabine
treatment than the RL-G tumors.
[3H]Gemcitabine uptake, metabolism and incorporation 
into nucleic acids
To assess whether a nucleoside transport defect was a con-
tributing factor to the gemcitabine resistance of RL-G cells,
the initial uptake rates (2–10 s) of 10 µM [3H]gemcitabine
by RL-7 and RL-G cells were compared, either in the
absence or presence of excess (100-fold) non-radioactive
gemcitabine. Both RL-7 and RL-G cells were able to trans-
port [3H]gemcitabine with comparable initial uptake rates
of 0.81 ± 0.28 and 0.5 ± 0.22 pmol/106 cells, respectively
(Fig. 2A). In the presence of excess non-radioactive gem-
citabine, initial uptake rates were decreased by 72% (RL-
7) and 65% (RL-G), indicating that the uptake of
[3H]gemcitabine was mediated by a transporter in both
cell lines. The initial uptake rates of 10 µM [3H]uridine, a
physiologic nucleoside, by RL-7 and RL-G cells were also
measured and found to be comparable to those measured
with gemcitabine (data not shown). These data suggested
that RL-G cells were capable of transporting nucleosides
intracellularly and that a transport defect was not involved
in the gemcitabine-resistance mechanism.BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/8
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Although RL-G cells were capable of inward nucleoside
transport, the cells were only able to metabolize [3H]gem-
citabine in trace amounts over a 4 h exposure period as
shown by the lack of measurable phosphorylated metab-
olites detected by HPLC analysis. Trace amounts of
[3H]dFdCTP could be detected in some samples if the
scale was greatly amplified. In contrast, RL-7 cells accumu-
lated 16.4-fold more [3H]gemcitabine-derived com-
pounds than RL-G cells (Fig. 2B). Approximately 90% of
the total radioactivity measured in acid extracts of RL-7
cells was recovered as the cytotoxic triphosphate (2.2
µmol/mg protein) and diphosphate (0.98 µmol/mg pro-
tein) derivatives with a [3H]dFdCTP/[3H]dFdCDP ratio of
2.3. ATP/ADP ratios for untreated vs. gemcitabine-treated
cells, were 3.6 vs. 2.8 for RL-7, and 3.1 vs. 2.1 for RL-G,
respectively. Since gemcitabine has the ability to be incor-
porated into both DNA and RNA, the amount of
[3H]gemcitabine present in the nucleic acid extractions
was determined. No [3H]gemcitabine was detected in the
DNA or RNA of RL-G cells as expected (Fig. 2C). In RL-7
cells, the incorporation of [3H]gemcitabine was higher in
genomic DNA (11.9-fold) than in total RNA (Fig. 2C).
Detection of gemcitabine-induced cell cycle perturbations 
and cell cycle-related events
Flow cytometry of RL-7 and RL-G cells demonstrated a
diploid cell population. After 24 h of continuous expo-
sure to gemcitabine, a substantial accumulation of RL-7
Median tumor weight in mg in nude Swiss female mice xenografted with RL-7 or RL-G cells and treated with gemcitabine (200  mg/Kg i.p. once a week; 6 doses) or untreated Figure 1
Median tumor weight in mg in nude Swiss female mice xenografted with RL-7 or RL-G cells and treated with 
gemcitabine (200 mg/Kg i.p. once a week; 6 doses) or untreated. RL-7 control : mice injected with RL-7 cells, 
untreated; RL-7 Gem : mice injected with RL-7 cells, treated with gemcitabine; RL-G control : mice injected with RL-G cells, 
untreated; RL-G Gem : mice injected with RL-G cells, treated with gemcitabine.
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Comparative uptake of [3H]gemcitabine and incorporation into nucleic acids of RL-7 and RL-G cells Figure 2
Comparative uptake of [3H]gemcitabine and incorporation into nucleic acids of RL-7 and RL-G cells. (A) Cells 
were exposed to [3H]gemcitabine for 2–60 s. (B) Accumulation of [3H]gemcitabine in RL-7 and RL-G cells over a 4 h exposure 
period. Each time point represents the average (± S.D.) of three determinations (C) Incorporation of [3H]gemcitabine (pmol/
mg) into nucleic acids after a 4-h exposure in two separate experiments.
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cells in G0/G1 phase was observed with a decrease in the
G2/M fraction (Table 2). At 72 h, a maximal arrest of cells
in the S phase fraction (84%) was detected. The G0/G1
fraction dropped dramatically as the cells moved into S
phase. Conversely, in RL-G cells gemcitabine treatment
slightly arrested the cell cycle in S-phase at the expense of
the G2/M fraction (Table 2). No G1 phase arrest was
observed in this cell line (Table 2).
Comparison of apoptosis and apoptotic pathways 
between RL-7 and RL-G cells
Exposure of cells for 24 h and 72 h with gemcitabine
caused a proportional increase of annexin-V staining typ-
ical of apoptosis in RL-7 cells. However, the amount of
apoptotic cells did not increase in the RL-G cell line (Fig.
3A). Poly-(ADP-ribose) polymerase (PARP) cleavage was
detected after 72 h of exposure to gemcitabine of RL-7
cells (Fig. 3B). As shown in Figure 3C, no significant mod-
ifications of the anti-apoptotic protein Bcl-2 and the pro-
apoptotic protein Bax levels were detected after gemcitab-
ine exposure.
Analysis of factors involved in gemcitabine metabolism and 
drug targets by quantitative reverse-transcriptase 
polymerase chain reaction (RT-PCR)
To test whether resistance of RL-G cells to gemcitabine
was due to multiple mechanisms, the mRNA levels of sev-
eral biological parameters (and potential drug targets)
involved in gemcitabine metabolism, were analyzed by
real time-PCR. According to quantitative RT-PCR results
shown in Figure 4A, RL-G cells had no detectable dCK
expression compared to RL-7 cells. In contrast, the 5'-
nucleotidases, cN-II and dNT-2, were slightly increased in
RL-G cells (2-fold). Similarly, expression levels of hENT1
and RNR subunits 1 and 2 were increased in 2.7-, 3.4- and
1.8-fold in RL-G cells, respectively (Figure 4B). hENT2, 5'-
nucleotidase dNT1 and DNA POL mRNA were expressed
at similar levels in both cell lines. Neither RL-7 cells nor
RL-G cells expressed detectable CDD (data not shown).
PCR analysis of dCK gene
To determine the cellular modification responsible for
dCK mRNA down-regulation, we performed a qualitative
study of the dCK gene. For this purpose, exons of the dCK
gene as well as 5'-untranslated regions were amplified by
PCR as described in the methods section. Figure 5 shows
PCR products obtained using genomic DNA from RL-7
and RL-G cells. In resistant RL-G cells, no amplicons were
obtained for regions located before the fourth exon, sug-
gesting a partial deletion of the dCK gene in this cell line.
Exons 4, 5, 6 and 7 of the human dCK gene were ampli-
fied in both cell lines. These results suggest a genetic mod-
ification of the dCK gene in RL-G cells.
Discussion
Our results show that dCK-deficient RL-G lymphoma cells
are resistant to gemcitabine both in vitro and in vivo. RL-G
cells accumulated only trace amounts of phosphorylated
derivatives of [3H]gemcitabine compared to their parental
counterpart. This lack of accumulation was not due to
decreased inward transport of gemcitabine by nucleoside
transporters because mRNA expression of nucleoside
transporters and the initial uptake rates measured were
similar for both cell lines. The lack of [3H]gemcitabine
nucleotide accumulation and incorporation into nucleic
acids in RL-G cells was explained by the lack of dCK
expression in these cells.
A relationship between lack of dCK expression and
decreased dFd-CTP accumulation has already been shown
by other investigators, both in selected and non-selected
cell lines which had various levels of dCK activity, includ-
ing dCK-deficient lines (reviewed in [15]). The observed
cross-resistance of the RL-G cells to other pyrimidine and
purine analogues may also be due to dCK deficiency.
Other authors have also shown cross-resistance of gemcit-
abine-resistant cells to other nucleoside analogues due to
dCK deficiency [7,24,25].
In keeping with the in vitro results, the RL-G mouse
xenografts were resistant to gemcitabine treatment in
contrast to the parental RL-7 tumors. These data are are
Table 1: Primer sequences used for semi-quantitative PCR assessment of the deoxycytidine kinase gene.
Exon Forward Primer 5'-3' Reverse Primer 5'-3' Product size
5'-UTR AGTCACCGTTTTCCCCTTCT CTTTGTTCAACACGCCAAAA 206
2 GGCAGGGAGCCTTTTCATTT CTCCTCTAAACCAAGAGGCT 339
3 CCAGACCTCAGACAATCTGA CCCAGCTCAGCCATTCATTA 490
4 GTGCCACTGGATTTAGGAGA GTTGGGAGGCTGGAGTTAAA 358
5 AGCGTGAGTAGAGAGACACA CGCTATCAATACCACCAAGG 439
6 CTGCCAGATGAAGTACTGCA TGTCAGATTCTGAGATTCCG 458
7 AGTTACTTATACAGCTGGGG TATCTGGAACCATTTGGCTGC 180BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/8
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Effect of gemcitabine (0.3 µM) on apoptosis and protein expression of PARP and pro- and antiapoptotic members of the Bcl-2/  Bax family Figure 3
Effect of gemcitabine (0.3 µM) on apoptosis and protein expression of PARP and pro- and antiapoptotic mem-
bers of the Bcl-2/ Bax family. (A) Flow cytometric detection of the Annexin-V staining in RL-7 and RL-G cells measured at 
different time intervals after incubation with gemcitabine 0.3 µM (B) PARP cleavage as detected by western blot after gemcitab-
ine treatment at different time intervals (C) Bcl-2 and Bax expression by western blot. RL-7 and RL-G cells were treated with 
gemcitabine 0.3 µM for 24 and 72 h and subsequently lysed, subjected to SDS-PAGE, and immunoblotted with the correspond-
ing monoclonal antibody as described in Material and Methods. The experiments shown are representative of two performed. 
C: control.
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Analysis of other known mechanisms of resistance to gemcitabine Figure 4
Analysis of other known mechanisms of resistance to gemcitabine. (A) Quantitative real time RT-PCR analysis of 
factors implicated in the activation or degradation of gemcitabine in RL-7 and RL-G cells; 18S ribosomal RNA (18S), deoxycyti-
dine kinase (dCK), high Km 5'-nucleotidase (cNII), 5'-3'-nucleotidase (dNT1) and mitochondrial 5'-nucleotidase (dNT2) (B) 
Quantitative real time PCR analysis of factors implicated in the transport and intracellular targeting of gemcitabine; human 
equilibrative nucleoside transporter 1 and 2 (ENT1; ENT2), ribonucleotide reductase M1 and M2 subunits (M1, M2) and DNA 
polymerase α (Pol). RT-PCR of these genes was performed as described in Material and Methods. Results are expressed as % 
of PCR arbitrary unit expression in RL-G cells related to RL-7 PCR arbitrary unit expression.
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consistent with the observations reported by other
authors. Ruiz van Haperen [18] demonstrated that human
ovarian carcinoma A2780 xenografts were highly resistant
to gemcitabine, mainly because of a decreased dCK activ-
ity. More recently, Blackstock [26] demonstrated that
transfection of the dCK gene into HT-29 human colon car-
cinoma xenografts resulted in increased expression of
dCK, enhanced dFd-CTP accumulation and a potentiated
in vivo tumor response to gemcitabine. Our results con-
firm a major role for dCK in in vitro and in vivo resistance
to gemcitabine.
To elucidate why dCK mRNA expression was absent in the
resistant cells, we analyzed the dCK gene by PCR. Our data
show that the deficiency in dCK mRNA expression as
detected by quantitative PCR is due to a partial deletion in
the 5'-region of the dCK gene developed during the step-
wise selection process with increasing concentrations of
gemcitabine. It was previously reported that deletions of
exon 3 conferred resistance to pyrimidine nucleoside ana-
logues in a human melanoma cell line [27]. Deletions of
exon 4 and 5 were also related with resistance to ara-C and
gemcitabine in leukemic, fibrosarcoma and ovarian cell
lines and leukemic blasts from acute myeloid leukemia
patients [18,27-29]. The nature of the deletion mutant
seems to be dependent on the nucleoside analogue which
was used for establishing resistant cells, although the
chemical structures and the molecular targets of these
nucleosides are similar.
It is common to observe the presence of multiple resist-
ance mechanisms when drug resistance is induced artifi-
cially in vitro by prolonged exposure [19,30]. Gemcitabine
resistance demonstrated by RL-G cells may involve minor
contributions from other resistance mechanisms in addi-
tion to dCK deficiency. Previous detailed investigations
using the purified ribonucleotide reductase have eluci-
dated the mechanism-based inhibition of this protein by
dFd-CDP [12]. In vitro data suggests irreversible binding of
the R1 subunit as the reasonable target for enzyme inacti-
vation [31]. Such inhibition of the R1 subunit depends on
the availability of dFd-CDP and on the synthesis of new
proteins to restore enzyme activity. Thus, an increase in
RNR-M1 expression may also have contributed to the
Semi-quantitative PCR assesment of exons 2 to 7 of the dCK gene and a 5'-untranscribed region Figure 5
Semi-quantitative PCR assesment of exons 2 to 7 of the dCK gene and a 5'-untranscribed region. Genomic DNA and PCR 
were performed as described in Methods section.BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/8
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resistance phenotype of RL-G cells. However, as indicated
earlier, RL-G cells accumulated only trace amounts of
phosphorylated derivatives of [3H]gemcitabine indicating
that the major mechanism of resistance to gemcitabine in
these cells involved drug activation.
RL-G cells also expressed a 2-fold increase of the 5'-nucle-
otidases cN-II and dNT-2. The role of 5'-nucleotidases in
gemcitabine resistance is controversial. We previously
observed that total 5'-nucleotidase activity was 14-fold
increased in K562 human leukemia cells selected for
resistance to gemcitabine [19]. In contrast, Schirmer [8]
demonstrated that cladribine-resistant HL60 cells express-
ing high levels of cN-II were not resistant to gemcitabine.
In addition, recent in vitro studies with different recom-
binant 5'-nucleotidases have not shown a direct degrada-
tion of dFd-CMP [32]. Thus, whether increased levels of
these two 5'-nucleotidases contribute to gemcitabine
resistance observed in our model is not clear.
In our model, RL-7 cells were more susceptible to gemcit-
abine-induced apoptosis than RL-G cells, in keeping with
previous evidence on the role of gemcitabine as a potent
inducer of apoptosis [22]. The presence of PARP cleavage
found in the RL-7 cells demonstrated that apoptosis may
involve the caspase-3 pathway. We also analyzed the
expression of Bcl-2 and Bax proteins. These two proteins
have opposing effects, with Bcl-2 serving to prolong cell
survival and Bax acting as an accelerator of apoptosis [33-
35]. Our results show no correlation between Bcl-2 and
Bax protein levels and the extent of apoptosis in
lymphoma cells exposed to gemcitabine. These results are
in agreement with the findings of Gazzit [36] who
reported that the extent of gemcitabine-induced apoptosis
is independent of the levels of Bcl-2 expression. However,
we have previously found that in breast cancer cells the
extent of apoptosis was correlated with Bcl-2 expression
[22], further supporting the cell type dependence of the
response of the apoptotic pathway.
Conclusions
In this human lymphoma model, the in vitro and in vivo
resistance to gemcitabine can mainly be attributed to the
partial deletion of dCK gene. Therapeutic strategies aim-
ing to overcome dCK deficiency may be useful in enhanc-
ing the cytotoxic effects of gemcitabine. In this setting,
stimulation of dCK activity can be induced by pre-treating
cancer cells with etoposide, other nucleoside analogues or
gamma radiation before gemcitabine administration [37-
40]. The effect seems to be cell-specific and dependent on
the administration scheme and the basal dCK levels. dCK
gene-directed therapies may also be useful in enhancing
the cytotoxic effects of gemcitabine by affecting the
metabolism of the drug [26]. Another possibility would
be to administer mononucleotide prodrugs of gemcitab-
ine [41,42] bearing transient phosphate protectors that
would deliver the corresponding 5'-mononucleotide
inside the cell without requiring dCK activation. This
strategy has already shown succesful activity in overcom-
ing ara-C resistance due to dCK deficiency [23].
Methods
Reagents
Gemcitabine (Gemzar®) was a kind gift from Eli Lilly
(Indianapolis, IN, USA). Stock solutions were prepared in
distilled water and fresh dilutions were prepared before
each experiment. Dilazep, tri-N-octylamine, 1,1,2-trichlo-
rotrifluoroethane, propidium iodide and MTT were pur-
chased from Sigma-Aldrich (St. Louis, MI, USA). Bradford
protein assay solution was purchased from Bio-Rad Labo-
ratories (Ontario, Canada). [3H]Gemcitabine (14 Ci/
mmol) and [3H]uridine (17.7 Ci/mmol) were purchased
from Moravek Biochemicals Inc. (Brea, CA, USA). Ecol-
ite™ was purchased from ICN (Costa Mesa, CA, USA).
Antibodies against Bax were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA); antibodies
against Bcl-2 were purchased from DAKO (Glostrup, Den-
mark). Peroxidase-conjugated secondary antibodies were
purchased from Covalab (Oullins, France). Enhanced
chemiluminescence western blot detection reagents (ECL
system) were purchased from Amersham (Amersham
Corp, Buckinghamshire, UK). Other reagents used were
analytical or HPLC grade and commercially available.
Cell lines
The RL-7 cells are derived from a human follicular lym-
phoma [43]. The resistant variant RL-G was developed
using step-wise increases of concentration of gemcitabine
over a 12 month period. The maximum concentration
used during selection was 2 µM. All cells were grown on
25 cm2 flasks at 37°C in RPMI containing 10% fetal calf
serum, 1% L-glutamine and 2% penicillin-streptomycin
in a humidified atmosphere containing 5% CO2.
[3H]Gemcitabine transport and accumulation
Cellular uptake assays using suspensed cells have been
described previously [2,44]. Assays (106 cells/tube) were
conducted at room temperature in transport buffer (20
mM Tris/HCl, 3 mM K2HPO4, 1 mM MgCl2.6H2O, 2 mM
CaCl2, 5 mM glucose and 130 mM NaCl, pH 7.4, 300 ± 15
mOsm) at various time intervals. Cell pellets were lysed
with 5% Triton X-100 and mixed with Ecolite™ scintilla-
tion fluid to measure the cell-associated radioactivity
(Beckman LS 6500 scintillation counter; Beckman-Coul-
ter Canada, Mississauga, ON). Initial uptake rates were
measured over 2–10 s and drug accumulation was deter-
mined after exposure of cells to 10 µM [3H]gemcitabine
for 4 h.BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/8
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Extraction of nucleic acids for [3H]Gemcitabine 
scintillation assay
Exponentially growing RL-7 and RL-G cells were exposed
to 10 µM [3H]gemcitabine for 4 h at 37°C. Cells were
harvested by centrifugation and washed with phosphate-
buffered saline. Aliquots (5 × 106 cells) were snap-frozen
in liquid nitrogen and stored at -70°C before HPLC anal-
ysis and nucleic acid extraction. DNA was isolated using a
Wizard genomic DNA kit (Promega Corp., Madison, WI,
USA). Total RNA was extracted using an RNA easy kit
(Qiagen, Valencia, CA, USA) and treated with RNase-free
DNase 1 (Pharmacia Biotech) to remove any DNA con-
tamination. Radioactivity incorporation was determined
by scintillation counting. Experiments were performed in
duplicate.
HPLC analysis
Cell pellets (prepared as described above) were extracted
with 10% trichloroacetic acid on ice for 15 min and cen-
trifuged to remove cell the protein precipitate. The acidic
extract was neutralized with 2 volumes of tri-N-
octylamine/1,1,2-trichlorotrifluoroethane (1:4) and the
aqueous layer passed through a 0.22 µm filter before
injection onto a Partisil SAX 10 column (250 × 4.6 mm
internal diameter). The resolution of the nucleotides was
achieved using a gradient (0%A-80%B) and based on a
method described by Gandhi [45]. Buffer A, 10 mM, pH
2.9; buffer B, 750 mM ammonium phosphate, pH 4.5.
The flow rate of the eluent was 1.5 mL/min and was mon-
itored by UV absorbance (260 nm). Fractions were also
collected for radioactivity measurements on a scintillation
counter.
RNA extraction, RT-PCR and quantitative PCR
The level of mRNA expression of metabolic factors
involved in gemcitabine resistance was assessed by quan-
titative real time RT-PCR, performed in a LightCycler
detection system (Roche, Mannheim, Germany) as previ-
ously described [22]. Briefly, cDNA (5 µl) was mixed with
primers (300 nM each), LightCycler-FastStart DNA Master
SYBR Green I (Roche) (hENT1, hENT2, CDD, RNR-M1,
RNR-M2 and DNA POL) or LightCycler-FastStart DNA
master hybridization probes (Roche) (18S, dCK, cNII,
dNT-1 and dNT-2), and probes (130 nM; if necessary) in
a total volume of 20 µl. These reactions were prepared in
duplicate. Primers and probes sequences for hENT1, dCK,
CDD, cNII, dNT-1, RNR-M2 and DNA POL are published
elsewhere [22]. Primers for hENT2 were as follows: for:
atgagaacgggattcccagtag ; rev: gctctgattccggctcctt. Primers
for RNR-M1 were as follows: for: gcagctgagagaggtgcttt; rev:
aatggttgtagaattaagaatagc. Primers and probes for dNT-2
were as follows: for: catcagcatttgggagtcaa; rev: cgacacaatct-
gctccagaa; probe: 5'-fam-cgtcttcatctgcacaagcccca-tamra. All
samples were analyzed in three separate experiments.
For each sample (RL-7 or RL-G cell lines) and the calibra-
tor (K562 cell line), the relative amount of a target gene
and a reference gene (18S) were determined. Crossing
point values (Ct), which are the PCR cycle numbers at
which the accumulated fluorescent signal in each reaction
crosses a threshold above background, were obtained
with the LightCycler software 3.5 (Roche) using the sec-
ond derivative maximum method. (Ct) values are a func-
tion of the amplification efficiency of the respective PCR.
These data were then exported into the RelQuant software
(Roche) as *.txt files. This software provides efficiency-
corrected, calibrator-normalized quantification results.
Results are expressed as the target/reference ratio of the
sample divided by the target/reference ratio of the calibra-
tor and therefore are corrected for sample inhomogenities
and detection-caused variances. The efficiency-corrected
quantification performed by Relquant is based on relative
standard curves describing the PCR efficiencies of each tar-
get and the reference gene. The relative standard curves are
determined and are used for each analysis.
Ratio results obtained with the RelQuant software were
considered as final relative PCR arbitrary units. Results
were then expressed as % of PCR arbitrary units in RL-G
cells related to RL-7 cells PCR arbitrary unit expression.
DNA extraction and PCR assay for the dCK gene
Genomic DNA was prepared with a phenol/chloroform
extraction method [46]. The coding sequence of the 7 last
exons of the human dCK gene were amplified in a final
reaction volume of 25 µl using PCR primers (Table 1), Taq
DNA polymerase (Invitrogen) and 250 ng of genomic
DNA. The PCR program profile was: 10 min at 94 °C fol-
lowed by 50 cycles of 30 sec at 94 °C, 30 sec at 60 °C and
30 sec at 72 °C. The PCR products were separated on aga-
rose gel 1,5% using low molecular DNA weight (Invitro-
gen) as marker of size.
Flow cytometric detection of cell cycle and apoptosis
For analysis of DNA content and cell cycle distribution,
RL-7 and RL-G cells were treated with gemcitabine 0.3 µM
for 24 h and 72 h. After drug-exposure, 106 cells/ml were
resuspended in 2 ml of propidium iodide solution (50 µl/
ml), incubated at 4°C overnight and then analyzed by
flow cytometry. For apoptosis determination, we used the
Annexin-V-Fluos Staining Kit (Boehringer Mannheim,
Gmbh, Germany) as recommended by manufacturers.
Flow cytometry was performed on a FACScalibur (Becton
Dickinson, San Jose, CA, USA). For determination of the
apoptotic fraction, analysis was performed using Cel-
lQuest™ software (Becton Dickinson, San Jose, CA, USA).
Cell cycle distribution and DNA ploidy status were calcu-
lated after exclusion of cell doublets and aggregates on a
FL2-area/FL2-width dot plot using Modfit LT 2.0™ soft-
ware (Verity Software Inc, Topsham, ME, USA).BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/8
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Western Blots
Protein expression was determined by western blot analy-
sis in untreated RL-7 and RL-G cells and after 24 h
incubation with gemcitabine 0.3 µM. Briefly, protein was
extracted from cells with cold lysis buffer (20 mM Tris-
HCL pH 6.8, 1 mM MgCl2, 2 mM EGTA, 0.5% NP40, STI
1 mg/ml, leupeptin 100 µg/ml, aprotinin 100 µg/ml, ben-
zamidine 30 mg/ml, TPCK 1 mg/ml and PMSK 5 mg/ml).
Cell lysates were resolved by 12% SDS-PAGE, and trans-
ferred onto a nitro-cellulose membrane (Hybond-ECL,
Amersham Corp, Buckinghamshire, UK). The blots were
incubated with the appropriate dilution of primary anti-
body, followed by incubation with peroxidase-conjugated
secondary antibody. Protein signals were detected by
chemiluminiscence and exposure to Kodak film (Eastman
Kodak Company, Rochester, NY, USA). Horizontal scan-
ning densitometry was performed on western blots by uti-
lizing acquisition into Adobe PhotoShop (Apple,
Cupertino, CA, USA).
Animal studies
Experiments were performed in 4 week-old female ath-
ymic nude mice (IFFA-CREDO, L'Arbresle, France). The
animals were kept in conventional housing. Access to
food and water was not restricted. RL-7 and RL-G
xenografts were developed in groups of five mice. Each
animal (average body weight 25 g before injection)
received a subcutaneous injection in the right flank area
containing 106 RL-7 or RL-G cells in serum-free RPMI
1640 (day 0). After 24 h, gemcitabine was given intraperi-
toneally at a dose of 200 mg/kg once a week (6 doses; 3
consecutive weeks followed by 1 resting week) in the
treated group. Initial drug toxicity studies were performed
in non-tumor bearing mice at these doses and no major
toxicities were observed (weight loss <10%).
The mice were inspected daily for s.c. tumor development
and evaluation of clinical condition, and once tumor
development occurred, tumor size was determined by cal-
iper measurements while monitoring changes in animal
weight twice a week. Animals were euthanized when their
total tumor burden reached approximately 5,000 mg
(15% of body weigth) to avoid animal discomfort or if
clinical conditions may anticipate the potential for animal
suffering.
The endpoints for assessing tumor activity were as fol-
lows: (a) tumor weight (mg) = (A × B2)/2, where A and B
are the tumor length and width (in mm), respectively; (b)
tumor growth inhibition = T/C, where T is the weight of
treated tumor and C is the weight of control group, both
evaluated at 60 days after injection. All studies involving
mice were performed under Institutional Review Board-
approved protocol.
List of abbreviations used
dFdC, gemcitabine; hENT1, human equilibrative nucleo-
side transporter 1; dCK, deoxycytidine kinase; CDD, cyti-
dine deaminase; 5 NT, 5'-nucleotidase; RNR-M1,
ribonucleotide reductase subunit M1; RNR-M2, ribonu-
cleotide reductase subunit M2; MTT, 3-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyl-tetrazolium bromide; IC50,
inhibitory concentration 50; DNA POL, DNA polymerase
α.
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Table 2: Analysis of flow cytometric cell cycle distribution before and after exposure to gemcitabine (0.3 µM) a.
RL-7 RL-G
C o n t r o l 2 4  h7 2  hC o n t r o l 2 4  h7 2  h
G1 53.2 ± 9.0 63.3 ± 1.5 15.0 ± 1.4 39.7 ± 7.5 38.2 ± 6.4 40.9 ± 2.6
S 39.2 ± 3.0 36.5 ± 1.3 84.7 ± 1.4 46.3 ± 10.6 50.3 ± 8.5 51.6 ± 1.4
G2/M 7.4 ± 6.1 0.3 ± 0.1 0.2 ± 0.3 13.8 ± 3.2 11.2 ± 2.2 7.2 ± 1.4
a The reported values (mean ± SD, n = 3) are expressed as percentage of total cells.BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/8
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